Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|November 10, 2014
AZD9291 in Advanced NSCLC
Author(s)Susan Galbraith, MD, PhD
Susan Galbraith, MD, PhD, provides an overview of the ongoing phase I/II AURA study.
Advertisement
Clinical Pearls
Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, provides an overview of the ongoing phase I/II AURA study, which aims to evaluate AZD9291 for patients previously treated with an EGFR TKI with advanced non-small cell lung cancer (NSCLC) with the T790M mutation.
- The confirmed overall response rate was 70% in patients treated with 80 mg of AZD9291.
- Responses are durable – median PFS is 9.6 months. Today, the only option for this group of patients is chemotherapy, which elicits PFS of 3-4 months.
- AZD9291 is associated with reduced rates of rash and diarrhea compared with chemotherapy.
Advertisement
Related to this article
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5